viewTissue Regenix Group PLC

Tissue Regenix makes strong operational and financial progress

Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”

surgeons working
The company - a regenerative medicines specialist

Tissue Regenix Group PLC (LON:TRX) said it remained committed to hitting its target of breaking even by 2020 as its interim results revealed the company delivered strong financial and operational performances.

Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”.

In the six months ended June 30, it inked distribution agreements with Arthrex and ARMS Medical of the US and Pennine Healthcare here in the UK.

Another milestone was British regulatory sign-off for the BioRinse portfolio, while the manufacturing of DermaPure, the company’s wound care product, has been successfully transferred to the CellRight facility in Texas ahead of schedule.

WATCH: Tissue Regenix boss gives his take on results

Financially, significant progress was made with revenues rising to £5.6mln in the first half from £1.3mln in the comparable period last year, boosted by sales of DermaPure, which almost doubled in value on a constant currency basis.

The contribution to the top line from the CellRight business, bought a year ago, was £3.2mln, which was up 46% on a like-for-like basis.

The company’s gross profit margin advanced 12.1 percentage points to 56%, while the underlying loss narrowed significantly from £5.1mln to £3.5mln.

Cash burn falls, plenty in the bank

At the same time, cash burn dropped by £300,000 to £4.3mln as Tissue Regenix said a research and development portfolio review had been undertaken and “operational efficiency initiatives implemented”.

The company had £12.2mln in the bank as at the end of June.

CEO Couldwell said he was pleased with the growing momentum across the business.

“As the demand for our products continues to increase we are proactively reviewing our capacity capabilities to ensure that we can scale the business to meet future production requirements,” he added.

“We have identified a number of potential new commercial opportunities which we are actively pursuing and anticipate our current momentum will continue. We remain committed to our objective of being break-even in 2020."

Shares rise 10%

The shares rose 10% to 9.62p following the update, valuing the business at almost £90mln.

“I am quite pleased,” said boss Couldwell of the interims. “But I am conscious this is one data point covering six months.

“The summer hasn’t been too unkind in terms of July and August, but we have some tough [comparable] numbers in the fourth quarter.”

Tissue Regenix’s products span wound care, orthopaedics and cardiac applications and are based on two proven regenerative medicine technologies.

The first, dCELL, removes cellular and DNA material from biological tissues, leaving intact a scaffold upon which the patient's cells can regenerate and re-populate.

BioRinse does a similar job killing micro-organisms, bacteria and spores as well as removing debris, blood, bone marrow and lipids. It is key to the process used to create CellRight-developed regenerative scaffolds used by surgeons.

Geographic expansion on the cards

Going forward, the company will focus on additional strategic partnerships alongside geographic expansion.

It is also targeting two firsts in the second-half: UK sales of BioRinse via its distribution deal with Pennine and US sales of SurgiPure XD, a soft tissue ‘patch’.

The company is also looking to expand its production capability at its facility in San Antonio, Texas, as well as rolling out initiatives designed to enhance employee engagement.

On the CellRight acquisition, CEO Couldwell said: “The integration in terms of nuts and bolts of finances and IT; it’s 95% done.”

Quick facts: Tissue Regenix Group PLC

Price: 1.1 GBX

Market: AIM
Market Cap: £12.89 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...



Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016


Price Monitoring Extension

2 weeks, 2 days ago

Directorate Change

2 weeks, 5 days ago

Holding(s) in Company

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 3 days ago

Second Price Monitoring Extn

3 weeks, 5 days ago

Price Monitoring Extension

3 weeks, 5 days ago

3 min read